Diovan for heart failure

The angiotensin II antagonist Diovan (valsartan) is now licensed for the treatment of symptomatic heart failure when ACE inhibitors cannot be used, or as add-on therapy to ACE inhibitors when beta-blockers cannot be used.

The recommended starting dose is 40mg twice daily, the dose may be titrated upwards to 80mg and 160mg twice daily at intervals of two weeks to the highest dose as tolerated by the patient.

The maximum daily dose administered in clinical trials was 320mg in divided doses.

Diovan may be administered with other heart failure therapies although the triple combination of an ACE inhibitor, a beta-blocker and Diovan is not recommended. An assessment of the patient's renal function should be carried out when initiating therapy with valsartan.

View Diovan drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...